The very first VITAL Biotech Accelerator Cohort has been selected, promoted by BARDA

Ten 10 startups has been selected jo join the first cohort of the Biotech Accelerator program of VITAL.

VITAL is a new accelerator hub in the U.S. Biomedical Advanced Research and Development Authority (BARDA) Accelerator Network (BAN). The BAN fosters growth of the global health security innovation ecosystem by supporting early-stage companies to overcome their business, marketing, and operational hurdles. VITAL supports development of next-generation therapeutic and vaccine technologies and platforms to promote health security, and is operated by Start2 Group, Advise Connect Inspire (ACI), and BioLabs.

Through the VITAL Biotech Accelerator, these companies will gain access to world-class mentorship, strategic industry connections, and vital resources to amplify their impact on global health. During the next 6 months, the selected companies will receive hands-on support through customized mentoring and sessions with domain experts.

From groundbreaking respiratory therapeutics to innovative vaccine platforms, this cohort represents cutting-edge solutions to enhance pandemic preparedness and health security. The companies of the first cohort are:

  1. Auravax Therapeutics, Inc.
  2. Avocet Bio GmbH
  3. Cryptyx Bioscience
  4. Cutanos GmbH
  5. Immunyx Pharma
  6. Macrotope Inc.
  7. Grant Knappe at Bathe BioNanoLab
  8. Nitro Biosciences
  9. Sagitta Biotech
  10. Thylacine Biotherapeutics

Learn about the program and its benefits here: https://lnkd.in/dFQA-zgR